Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Valneva SENASDAQ: VALN

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of €6.32M rose 11.2% year over year, behind the +138.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.2% from the prior quarter. Over 3 fiscal years it compounded at +1.1% a year.

Context

  • Depreciation & amortization amounted to 12.5% of revenue in FY2025, up 0.9 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +11.2% toward the trailing-twelve-month pace of +138.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€6.32M-2.2% QoQ
Last fiscal yearDec 2025
€21.75M+11.0% YoY
LTMMar 2026
€25.21M+138.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.2%——
1 year+11.0%——
3-year CAGR+1.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the cash flow

Latest · FY2025
21.75M EUR
Year-over-year change
+11.0%
4-year CAGR
+11.1%

Depreciation & Amortization vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +138.6% is the highest of 8, against a peer median of +4.6%.
  • Depreciation & amortization amounts to 16.1% of revenue for VALN, versus a peer median of 9.1%.
VALN Competitors
Depreciation & Amortization for VALN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$257M USD+23.6%-14.8%10.2%
PCVXVaxcyte, Inc.LTM Jun 2026$26.8M USD+40.0%+38.0%—
VALNValneva SELTM Mar 2026€25.21M EUR+138.6%+1.1%16.1%
NVAXNovavax, Inc.LTM Mar 2026$22.34M USD-50.0%-1.7%3.7%
VIRVir Biotechnology, Inc.LTM Mar 2026$18.23M USD+41.3%+46.1%27.8%
IBRXImmunityBio, Inc.LTM Sep 2026$16.54M USD+4.6%-5.3%9.1%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.99M USD-3.9%-18.4%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$2.88M USD-16.2%+25.6%6.4%
Peer median (excluding VALN) —+4.6%-1.7%9.1%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
Deferred Income Tax3.45M(1.54M)2.8M761K1.07M
Stock-Based Compensation14.51M(8.66M)5.11M7.98M9.53M
Change in Working Capital36.13M(145.98M)(145.06M)(11.57M)(148K)
Accounts Receivables(21.35M)12.4M(2.86M)15.71M13.33M
Inventory(92.37M)84.22M(9.17M)(6.8M)1.03M
Accounts Payables35.24M(14.05M)(17.4M)00
Other Working Capital114.61M(228.55M)(115.65M)(20.48M)(14.51M)
Other Non-Cash Items81.96M33.07M18.25M(71.72M)30.09M
Operating Cash Flow76.9M(245.34M)(202.74M)(67.22M)(52.89M)
Capital Expenditures(93.17M)(29.32M)(14.31M)(16.44M)(4.48M)
Acquisitions (Net)08K(10.95M)00
Purchases of Investments00000
Sales of Investments0000841K
Other Investing Activities55K260K4.6M90.78M1.87M
Investing Cash Flow(93.12M)(29.05M)(20.59M)76.92M(1.71M)
Debt Repayment(3.9M)34.49M75.89M(6.49M)61K
Common Stock Issued166.82M189.84M0030M
Common Stock Repurchased00(240K)00
Dividends Paid00000
Other Financing Activities(8.42M)(9.21M)(12.57M)(19.97M)(30.69M)
Financing Cash Flow154.5M215.12M63.08M30.68M(621K)
Effect of Forex Changes3.96M(828K)(204K)1.81M(3.4M)
Net Change in Cash142.29M(57.21M)(160.45M)42.19M(58.62M)
Free Cash Flow(16.27M)(274.67M)(217.06M)(83.66M)(57.38M)

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.